However, these outcomes cannot be generalized to the whole spectrum of CMD as this study did not evaluate endothelial-dependent pathways, nor CMD without CAD, which in fact might represent the population with the greatest benefit from SGLT2-is. The gene discussed is SLC5A2; the disease is coronary artery disorder.